Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FWIW, personally I like the fact you are now keeping the IBOX updated daily rather than posting every sell signal. This is going to force me to make my own sell decisions rather than depend on your hand holding. In the long run, this hopefully will make me a better trader.
My jr year resolution is to not follow so many picks down into the toilet. I am holding alot of crap right now that I should have dropped long ago. Again, it is taking responsibililty for my own trading decisions. Gotta learn to take a small loss and move on instead of hoping for better times as the stock plumets. Planning to hold until end of year tax time and then clean house.
Keep up the great work you do here my friend.
Aggie...
Chart - What is your target for EDS? Expect a TMI type move? Is this a fundamental play or do you see something in the chart? I see the big recent candle and concerned about picking something that may be topping out...Thank you in advance for your guidance..Aggie...
I got out at 1.20 from 1.00 entry. 20% !!!! Aggie....
IPII ($1.42) just made a +.30 jump in last 45 minutes...Anyone know whats up....Chart you still in from your 09/14 Alert??? TIA...Aggie....
Posted by: Chartinator Date: Monday, September 14, 2009 10:35:42 AM
In reply to: None Post # of 114421
University Alert
Bought 10k IPII at 1.74
Going to do a big boom boom. Tiny float
Form 8-K for SUNRISE SENIOR LIVING INC
--------------------------------------------------------------------------------
7-Oct-2009
Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement
On October 1, 2009, Sunrise Pasadena CA Senior Living, LLC ("Sunrise Pasadena") and Sunrise Pleasanton CA Senior Living, L.P., ("Sunrise Pleasanton" and together with Sunrise Pasadena, the "Sunrise Land Borrowers") entered into a letter agreement (the "Letter Agreement") with Wells Fargo Bank, National Association ("Wells Fargo") regarding that certain Loan Agreement dated September 28, 2007 (the "Loan Agreement") by and between the Sunrise Land Borrowers and Wells Fargo. Both Sunrise Land Borrowers are subsidiaries of Sunrise Senior Living, Inc. ("Sunrise"). Sunrise Pasadena owns undeveloped land located in Pasadena, California, and Sunrise Pleasanton owns undeveloped land located in Pleasanton, California.
Pursuant to the Letter Agreement, among other matters, Wells Fargo agreed to (i) extend the maturity date of the Loan Agreement from October 1, 2009 to November 16, 2009 (the "Extended Maturity Date") and (ii) forbear from enforcing its rights or remedies with respect to breaches of certain financial covenants contained in the Loan Agreement until the earlier to occur of (x) the Extended Maturity Date and (y) any other default under the Loan Agreement. As of October 1, 2009, there was approximately $22 million in outstanding borrowings under the Loan Agreement.
The Sunrise Land Borrowers' obligations under the Loan Agreement are secured by mortgages on the real property owned by the Sunrise Land Borrowers and are guaranteed by Sunrise.
--------------------------------------------------------------------------------
XTEX - Touching $5.00 PM...Up from $4.50 close...Not sure how many are still holding from the 09/16 alert....Aggie...
Posted by: Chartinator Date: Tuesday, September 15, 2009 2:51:44 PM
In reply to: None Post # of 111267
University Alert
In XTEX here at 4.49 x 5000 shares. Chart breakout
THLD up nice PM....Aggie...
I am not sure if it means additional signings at all...I do know it means in a court of law the patents are confirmed and valid...I do not expect as much litigation as in the past...Therefore, IMO, the pressure builds for all companies who do not already have a license...
I exited about a year ago because of all the hoopla surrounding the patent review...price eroded significantly...I always expected to reenter if the ruling was favorable to PTSC...It was, and now I am back in at about half the PPS as when I exited...
All my humble opinion of course....Aggie.....
Back in today after a long absence...Great news today...Aggie..
Holy Cr@p batman...ACAS 3.13 PM...SRZ 2.80 PM...LBIX 1.00 PM...Unfreaking believeable...Aggie....
For me, and everyone uses their own system...I use a stop loss until I am green...once green (and depending on how much), I either set a GTC sell or a trailing stop loss...I usually check my stocks 2-3 times per day and adjust accordingly...Many times my GTC sell hits while I am away and I miss the really big runners...But, I'm not complaining...Good luck to everyone....Aggie....
I usually set my stop loss at about 10%...Only because I have confidence that the WU picks will go up...We do not play many pinks here and for these I have a little tighter stop loss...
I usually buy in 1K share increments...And never average down more than twice...This is where I do get stuck from time to time, so at some point I need to refine my strategy for taking a loss...For me, that is the hardest thing to do...And I am getting spoiled here at WU...Some stocks I may hold for a month or so, but they almost always go up...Sold FTK yesterday for a small profit...Entry was in June...Averaged down twice...
I wish you the best of luck...Follow the picks here as all have passed the WU tests...Set your exit points (both + and -) and develope a plan that works for you...
Cheers....Aggie....
I use Ameritrade, they have many types of order you can place....Aggie...
Elcheepo - I am in the same boat as you...I can only check my stocks a couple times per day...I miss alot of the runners...Once I am in a stock, I always put in a stop loss at first...This protects me on the back end...Once the stock starts moving some...I will put in a GTC sell at about 10%...and I adjust these daily depending on how the stock has moved...I almost always get out before chart and company do because of my GTC sell, but I am making more money trading with this board than I ever have on my own...Just something to think about....Aggie...
Funny Jake...I was thinking of a long lost love from my college days...Aggie....
TDAmeritrade cancelled my GTC sell order for XOMA @ 1.00...Never seen this happen before....Big news hit the wires early today ...Hope this means a large gap up...Got my fingers crossed....Aggie...
http://finance.yahoo.com/news/XOMA-Announces-Plan-to-Fully-pz-3692641789.html?x=0&.v=1
XOMA Announces Plan to Fully Repay Goldman Sachs Loan
Press Release
Source: XOMA Ltd.
On Monday September 14, 2009, 7:30 am EDT
Buzz up! 0 Print
Companies:XOMA Ltd.
Genentech Agrees to Buy Back its LUCENTIS Royalty Obligation
Company to Host Conference Call and Webcast at 8:30 am ET Today
BERKELEY, Calif., Sept. 14, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA - News) today announced a plan to fully repay its loan with Goldman Sachs Specialty Holdings, Inc. (Goldman Sachs) using a combination of funds. These include proceeds from Genentech's payment to XOMA for Genentech's buyout of its LUCENTIS(R) royalty obligation to XOMA, the sale of common stock and the use of funds from an existing restricted cash account reserved for loan repayment. The repayment plan resolves the uncertainty about the loan that arose from the sudden and unexpected withdrawal of RAPTIVA(R) from the market earlier this year, which triggered XOMA to begin to renegotiate the loan that was secured by royalties from RAPTIVA, LUCENTIS and CIMZIA(R). Full repayment of the loan will discharge all of XOMA's obligations to the lenders.
"We are pleased to announce this plan that will strengthen XOMA's financial condition by removing the financial overhang of a loan repayment and ongoing interest payments and avoiding refinancing costs and future loan constraints. It will strengthen our balance sheet, reduce monthly costs and improve XOMA's freedom to operate," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. "Using the LUCENTIS royalty buyout payment to help fund the loan repayment is non-dilutive to shareholders and eliminates potential uncertainties related to LUCENTIS's future. Eliminating the loan overhang will also strengthen our position in negotiating future collaborations, including our antibody technology collaborations and a corporate partnership for XOMA 052."
"XOMA has been gaining momentum in the last few months by achieving a number of key milestones -- positive XOMA 052 Phase 1 results, a new antibody technology collaboration with Cephalon's subsidiary Arana and a new government SARS biodefense contract -- and this plan gives us the ability to focus on operating the business and achieving upcoming milestones, " said Mr. Engle.
XOMA plans to pay the $44.2 million in principal and interest due under the Goldman Sachs loan with $25 million from Genentech, $12.3 million in equity financing proceeds, $6.1 million from the company's restricted cash account, and $0.8 million from XOMA's unrestricted cash for a total of $44.2 million. As such, this combination of transactions is essentially cash flow-neutral since the royalty revenues have been applied exclusively to the loan repayment.
Under the new agreement with Genentech, XOMA receives $25 million in exchange for rights to all future LUCENTIS royalty payments. The common stock offering under XOMA's existing committed equity financing facility with Azimuth Opportunity Ltd., which is expected to close today, will provide net proceeds of approximately $12.3 million from the sale of 16,295,996 shares at an average price of $0.75 per share. Funds from the restricted cash account include $6.1 million from past royalty payments. Repayment of the loan eliminates the interest expense which would have been an annualized $4.8 million for 2009.
XOMA elected to pursue a buyout by Genentech of the future LUCENTIS royalty stream at the present time in part because of several potential near-term uncertainties including Genentech's plans to move the manufacturing of LUCENTIS overseas and potential future pressure on LUCENTIS sales from the impact of an ongoing clinical trial of LUCENTIS and Avastin(R). Based on XOMA's patents, XOMA had expected LUCENTIS royalties for the next five years. The last U.S. patent expires in 2014 and the European patents have already expired. If Genentech succeeds with publicly announced plans to open a manufacturing facility outside of the U.S. in 2010, XOMA would expect to lose rights to royalties on ex-U.S. sales of LUCENTIS which it is currently receiving and its LUCENTIS royalty revenue would be reduced significantly.
After the repayment, XOMA will continue to receive royalties from CIMZIA(R) sales and will be able to use them for to fund its operations. XOMA receives royalty revenue from U.S. and Swiss sales of CIMZIA(R), which is being launched in the U.S. by UCB, S.A. for the treatment of rheumatoid arthritis and is approved for treatment of Crohn's disease.
Conference Call and Webcast
XOMA will conduct a conference call and webcast to discuss these developments at 8:30 am Eastern time (5:30 am Pacific time). The webcast can be accessed via the Investors section of XOMA's website at http://investors.xoma.com and will be available for replay until close of business on November 13, 2009. Telephone numbers for the live audiocast are 800-441-0022 (U.S./Canada) and 719-457-2640 (international). A telephonic replay will be available beginning approximately two hours after the conclusion of the call until close of business on September 21, 2009. Telephone numbers for the replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international), passcode 9540633.
About XOMA
XOMA discovers, develops and manufactures therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 3AB, a biodefense anti-botulism antibody candidate.
XOMA has multiple revenue streams resulting from the licensing of its antibody technologies, product royalties, development collaborations, and biodefense contracts. XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.
The company has a premier antibody discovery and development platform that incorporates leading, unmatched capabilities in antibody phage display and a unique collection of antibody display libraries, as well as XOMA's proprietary Targeted Affinity Enhancement technology for antibody humanization and bacterial cell expression and manufacturing technologies. Bacterial cell expression is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses. XOMA recently signed a $6 million agreement with Arana Therapeutics subsidiary of Cephalon, Inc. (Nasdaq:CEPH - News) for a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display library, and a suite of integrated information and data management systems.
The company's integrated processes use proprietary informatics systems that:
* Increase efficiencies for data management and analysis
* Support rational data-driven decisions thus reducing costly
errors
* Increase capacity for multiple antibody programs with limited
resources
* Accelerate product development and
* Support intellectual property filings.
In addition to developing its own products, XOMA develops products with premier pharmaceutical companies including Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. XOMA has a fully integrated product development infrastructure and a team of approximately 190 employees at its Berkeley, California location. For more information, please visit http://www.xoma.com.
Forward-looking Statements
Certain statements contained herein concerning our plan to repay our loan with Goldman Sachs or product development or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including the facts that XOMA has not yet consummated its transactions with Genentech and Azimuth and that Goldman Sachs has not yet accepted XOMA's repayment plan; the declining and generally unstable nature of current economic conditions; the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); uncertainties regarding the status of biotechnology patents; uncertainties as to the cost of protecting intellectual property; changes in the status of the existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations; market demand for products; scale up and marketing capabilities; competition; international operations; share price volatility; XOMA's financing needs and opportunities; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.
The XOMA Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960
Contact:
XOMA, Ltd.Company and Investor Contact:Carol DeGuzman510-204-7270Mobile: 510 717 4642deguzman@xoma.comPorter Novelli Life SciencesMedia Contact:Carolyn Hawley
OT - Interesting perspective on Oboma healthcare...Sorry, I know off topic and this is not a politically themed board, but IMO important for ours and our childrens future....Aggie.
$heff,
This is why you have 1044 people marks. You put up with no BS on your board. Much respect and a whole bunch of profs....Aggie....
My 2cents...If you have only $500 to start, pick a good stock called by one of the professors(no pinks or otcbb) and go all in...Keep in mind there are never any guaruntees, but the stocks called here meet the boards criteria...it is very hard to make you commission back if you try to spread too thin...Once you have grown your account some, then deversify...Aggie..
I show .085 X .095....Ignored...Aggie....
LTXC breaking out PM....Up to 1.40 (+.31)....Aggie
Always set a stop loss, especially with Pinks...Can always get back in many times at a much better price if you like...IMO...Aggie....
Chart - Been in and out of RBY once already...Do you think still safe to jump back in again...Dont want to chase, but looks strong...Your thoughts...Thanks...Aggie..
VICL off the hook PM.....Aggie...
EDAP looking good PM....+.68 to $4.68....
YMI - GTC order hit at 1.90 from 1.56 entry...Aggie...
This recent move has nothing to do with the company...Simply momo players running the stock...everyone late to the party gets stuck...momo'ers run to the next mover and repeat...IMO...Aggie...
FRP - Out PM @ .82 from .75, .57 and .50 entries....Aggie...
Been following this board since December...My funds have now grown to the point I can participate in more plays...I usually buy 1K shares and try to track with the buy/sell alerts...However, I place GTC sells on all my stocks as I cannot watch daily...Therefore, I usually sell before chart does...August been a good month for me here at WU...Aggie...
Chart...I'm in em all!!!! Out of curiosity, how many positions are you holding at the moment. I'm pushing 20 or so and want to make sure I havent left something out...LOL...Aggie...
AI - Taking profits here at .509 from .45 entry....Aggie...
GKK - Taking my profits here at 1.80 from 1.50 entry...Aggie...
I'm already in....Never held as many positions as I currently have. GKK BEE LDK BPAX LLNW RBY TSTR YRCW YMI TMNG COIN FTY XCHO EVRM AI ALTU PLUG FRP
5 4 3 2 1 Blastoff.....Chug..Choke..ppppffftttttt
Looks like someone forgot to light the candle....
LDK looking good PM off China news...9.90 PM high...Aggie..
Pre-Market Trade Reporting
Pre-Market Charts | After Hours Charts Pre-Market
Last: $ 9.43 Pre-Market High: $ 9.90
Pre-Market Volume: 102,187 Pre-Market Low: $ 9.37
You seen any news in the past 2 years??? Last PR was 08/14/2007 which turned out to be complete BS....If you are in and no news is pushing this, be wary of the dump when these day traders get out. I sold my .0002's at .0007 today at open...If we do get some update from the company I will get back in...SPRL owes me, otherwise will watch for another entry...IMO...Aggie...
last PR: http://ih.advfn.com/p.php?pid=nmona&cb=1251214742&article=21863662&symbol=NO%5ESPRL
WOW!!!!
Out PNX @ 2.71 from 1.79 and 1.89
Out NXST @ 2.80 from 1.49
Out SVA @ 5.75 from 5.37 (this guy sold before I could adjust my GTC order... up too fast!!)
I dont know what to say other than THANK YOU!!!!!! Aggie....
Thanks Rick for the reply...This looks alot like the mini run last summer/fall...Turned out to be a whole lot of nothing...Maybe this time will be different...Hoping for continued interest tomorrow...Who knows, maybe Sam will put out something...Aggie....
I have played this stock many times in the past...Always alot of speculation with no substance...This stock seems to have one of these mini runs once a year...Is there anything other than speculation pushing this stock at this time???
I recognize many of the oldtimes still no this board...Anyone know anything??? Anyone spoken to VelvetMallet lately??? Always hoped SPRL would have its day...Still holding the 1M I picked up at .0002 way back in Feb...Aggie.......
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35682050